Get the Stockscreener App
2.25
4.17%
+0.09
After Hours:
2.21
-0.04
-1.78%
Acurx Pharmaceuticals Inc stock is currently priced at $2.25, with a 24-hour trading volume of 37,787.
It has seen a +4.17% increased in the last 24 hours and a +25.00% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.21 pivot point. If it approaches the $2.28 resistance level, significant changes may occur.
Previous Close:
$2.16
Open:
$2.15
24h Volume:
37,787
Market Cap:
$35.60M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-1.9912
EPS:
-1.13
Net Cash Flow:
$-9.80M
1W Performance:
+10.84%
1M Performance:
+25.00%
6M Performance:
-39.19%
1Y Performance:
-28.34%
1D Range:
$2.15
$2.2784
52W Range:
$1.17
$8.82
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917 533 1469
Address
259 Liberty Avenue, Staten Island
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
Acurx reports results from meeting with FDA regarding ibezapolstat - TipRanks.com - TipRanks
TipRanks
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Rises By 6.3% - Defense World
Defense World
Earnings call: Acurx Pharmaceuticals outlines ibezapolstat progress - Investing.com ZA - Investing.com South Africa
Investing.com South Africa
Earnings call: Acurx Pharmaceuticals outlines ibezapolstat progress - Investing.com India
Investing.com India
Earnings call: Acurx Pharmaceuticals outlines ibezapolstat progress - Investing.com India
Investing.com India
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Acurx Pharmaceuticals Inc (ACXP) Net Income 2024
ACXP net income (TTM) was -$14.58 million for the quarter ending December 31, 2023, a -20.55% decrease year-over-year.
Acurx Pharmaceuticals Inc (ACXP) Cash Flow 2024
ACXP recorded a free cash flow (TTM) of -$9.80 million for the quarter ending December 31, 2023, a -29.95% decrease year-over-year.
Acurx Pharmaceuticals Inc (ACXP) Earnings per Share 2024
ACXP earnings per share (TTM) was -$1.15 for the quarter ending December 31, 2023, a -2.68% decline year-over-year.
About Acurx Pharmaceuticals Inc
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York.
0.77%
1.20%
Cap:
|
Volume (24h):